Diabetic Macular Edema: Protecting Your Central Vision
Understanding Diabetic Macular Edema
The macula is a small, oval-shaped area near the center of the retina. It is responsible for the sharp, straight-ahead vision you use to read, drive, recognize faces, and see fine details. When the macula swells with fluid, these everyday tasks become difficult or impossible.
Unlike other parts of the retina that handle side vision, the macula provides the highest resolution sight. Even a small amount of swelling in this area can cause noticeable changes in how clearly you see.
Elevated blood sugar levels from diabetes gradually damage the small blood vessels that nourish the retina. Healthy retinal blood vessels have tight junctions that prevent fluid from leaking out. Over time, high blood sugar weakens these junctions, causing the vessels to become leaky.
When fluid escapes from damaged vessels, it collects in the macula and causes swelling. The retina has no lymphatic drainage system to clear this excess fluid, so the swelling persists. Low oxygen levels in the damaged retina trigger a chemical signal called vascular endothelial growth factor (VEGF). VEGF causes even more leakage and can stimulate the growth of fragile, abnormal blood vessels.
VEGF plays a central role in DME, but it is not the only factor. Tiny bulges in weakened blood vessel walls, called microaneurysms, also leak fluid into the retina. Inflammation from both the retina and the vitreous (the gel filling the eye) contributes to swelling as well. In some cases, scar tissue can pull on the macula, adding a tractional component to the edema.
Because multiple mechanisms drive DME, treatment sometimes needs to address more than VEGF alone. A retina specialist may consider different medications or combination approaches depending on how a patient responds.
Who Is Affected and Risk Factors
DME is the most common cause of irreversible vision loss in working-age Americans. Approximately 746,000 people aged 40 and older in the United States have DME, with a prevalence of 3.8% among adults with diabetes (NHANES, 2005-2008). In 2021, 9.6 million Americans had diabetic retinopathy, and 1.84 million had vision-threatening forms of the disease (CDC, 2021). DME prevalence was highest in the 65 to 79 age group, reaching 28.4% (CDC, 2021).
The problem is growing. Among commercially insured adults with diabetes, DME prevalence increased from 0.7% to 2.6% between 2009 and 2018 (CDC, 2023). This rise reflects both better detection and the increasing number of people living with diabetes.
The length of time a person has had diabetes is one of the strongest risk factors for developing DME. Having diabetes for 10 years or more increases the risk of DME 8.5-fold (NEI). DME can develop at any stage of diabetic retinopathy. It is especially common in people who have had diabetes-related retinal changes for an extended period.
Poor blood sugar control significantly increases the chances of developing DME. For every 1% increase in HbA1c (a measure of average blood sugar over two to three months), the risk of DME rises by 47% (NEI). Keeping blood sugar within a target range set by your medical team is one of the most effective ways to lower your risk.
DME does not affect all groups equally. Non-Hispanic Black adults have 2.64 times higher odds of developing DME compared to non-Hispanic white adults (NHANES, 2005-2008). The reasons for this disparity likely include differences in diabetes prevalence, access to care, and other health factors.
High blood pressure and high cholesterol also damage blood vessels throughout the body, including those in the retina. These conditions can accelerate the progression of DME and make it harder to treat. Managing blood pressure and cholesterol is an important part of protecting your eye health.
Signs and Symptoms
One of the most concerning aspects of DME is that it can develop silently. It is possible to have significant swelling in the macula without noticing any changes in vision. By the time symptoms become obvious, substantial damage may have already occurred. This is why regular eye exams are critical for anyone with diabetes.
When symptoms do appear, DME typically causes a general blurriness. It may feel similar to looking through the wrong prescription glasses. Tasks that require sharp central vision become more difficult. Common experiences include:
- Difficulty reading or seeing small print
- Trouble recognizing faces from a normal distance
- Blurred or wavy vision when watching television
- Colors appearing washed out or faded
- Difficulty driving safely, especially reading road signs
DME can affect one eye or both eyes. Sometimes one eye may have noticeable symptoms while the other appears normal. Even if only one eye seems affected, the other eye may also have early swelling that has not yet caused symptoms. A retina specialist can detect swelling in both eyes during a comprehensive examination.
Diagnosis and Testing
A dilated eye exam is the foundation of DME diagnosis. During this exam, a retina specialist places drops in your eyes to widen the pupils. This allows a clear view of the retina and macula. The specialist looks for signs of swelling, leaking blood vessels, microaneurysms, and other changes associated with diabetic retinopathy.
You cannot see or feel swelling in your own retina. Only an eye care professional using specialized equipment can detect it. This is one reason annual dilated exams are recommended for all people with diabetes.
Optical coherence tomography, or OCT, is a painless imaging test that takes detailed cross-section pictures of the retina. It measures the thickness of the macula with extreme precision. It also shows exactly where fluid has collected. OCT is the standard tool for diagnosing and monitoring DME.
Retina specialists use OCT images at nearly every visit to track how the macula responds to treatment. The scans take only a few seconds and do not require any injection or contact with the eye.
Fluorescein angiography is a test that maps blood flow in the retina. A yellow dye is injected into a vein in the arm. A special camera photographs the dye as it moves through the retinal blood vessels. Areas where vessels are leaking appear as bright spots on the images.
This test helps identify the specific blood vessels responsible for fluid leakage. It also shows areas of poor blood flow that may need attention. While OCT is used more frequently for routine monitoring, fluorescein angiography provides additional information that guides treatment decisions.
Treatment Options
Anti-VEGF injections are the primary treatment for DME. These medications block vascular endothelial growth factor, the chemical signal that drives leakage and abnormal blood vessel growth. Research has shown that anti-VEGF injections often produce better vision outcomes than laser treatment alone.
The injections are given directly into the vitreous cavity of the eye, a procedure called an intravitreal injection. While the idea of an eye injection can be concerning, the eye is numbed beforehand and the procedure takes only a few minutes. Most patients report mild discomfort rather than significant pain.
Several anti-VEGF medications are used to treat DME. Each works by blocking VEGF, but they differ in dosing intervals and specific properties.
- Lucentis (ranibizumab) was the first anti-VEGF medication approved by the FDA for DME in 2012, typically given every four weeks.
- Eylea (aflibercept) received FDA approval for DME in 2014 and is commonly given every four to eight weeks after initial loading doses.
- Vabysmo (faricimab), a bispecific antibody that blocks both VEGF and angiopoietin-2, can be dosed every four to sixteen weeks for DME.
- Avastin (bevacizumab) is FDA-approved for cancer treatment and is used off-label for eye conditions, including DME. It is typically given every four to six weeks.
- Eylea HD (high-dose aflibercept) offers extended dosing intervals up to five months (20 weeks) for DME patients showing a stable response after one year of treatment (FDA, 2026).
Some eyes with DME respond better to steroid medications than to anti-VEGF injections. Steroids reduce inflammation, which is one of the contributing factors in DME. Ozurdex (dexamethasone implant) is a tiny pellet placed inside the eye that slowly releases medication over several months. Intravitreal triamcinolone is another steroid option injected directly into the eye.
Iluvien (fluocinolone acetonide implant) is a long-acting steroid implant that can release medication for up to three years. Steroid treatments may be considered when a patient has not responded well to anti-VEGF therapy. Your retina specialist will weigh the benefits against potential side effects, which can include increased eye pressure and cataract development.
Laser photocoagulation (thermal laser treatment applied to the retina) was once the standard treatment for DME. While anti-VEGF injections have largely replaced laser as first-line therapy, laser still plays a role. It can seal leaking microaneurysms or reduce the overall treatment burden when combined with injections.
Laser is sometimes recommended for patients who cannot maintain a regular injection schedule. It may also be considered when DME involves leakage away from the very center of the macula. Your retina specialist will determine if laser is appropriate for your situation.
Recent developments are extending the time between treatments. Research shows that 71% of DME patients can achieve dosing intervals of 16 weeks or longer with newer therapies (FDA, 2026). In February 2025, Susvimo (ranibizumab injection) became the first FDA-approved continuous delivery port system for DME, requiring refills just twice yearly. This small refillable device is surgically placed in the eye wall and steadily releases medication.
What to Expect
Most anti-VEGF treatment plans begin with a series of monthly injections, often called loading doses. This initial phase typically involves three to six injections given four weeks apart. The goal is to quickly reduce swelling and stabilize the macula. After loading doses, your retina specialist will evaluate your response and adjust the treatment schedule.
Treatment for DME is usually a long-term commitment. Many patients require ongoing injections for months or years. The good news is that newer medications are making it possible to extend the time between visits for many patients.
Before each injection, your retina specialist will clean the eye and apply numbing drops or gel. The injection itself takes only seconds. Afterward, you may experience mild redness, a gritty feeling, or small floaters. These effects typically resolve within a few days. Most people can return to normal activities the same day or the next day.
Your retina specialist will schedule follow-up visits that include OCT imaging to measure how the macula is responding. Based on these results, the interval between injections may be shortened or lengthened.
Anti-VEGF treatment can significantly improve vision in many patients and prevent further vision loss in most. However, results vary from person to person. Some patients experience meaningful improvements in clarity, while others stabilize without gaining much vision back. Early detection and prompt treatment tend to produce the best outcomes.
DME is a chronic condition that can return if treatment is stopped too early. Missing appointments or delaying injections can allow the swelling to come back. This can lead to additional vision loss that may not be recoverable.
Living with Diabetic Macular Edema
The most powerful thing you can do to protect your eyes is to manage your diabetes carefully. Keeping blood sugar, blood pressure, and cholesterol within recommended ranges helps slow the progression of diabetic eye disease. Even small improvements in blood sugar control can make a meaningful difference over time.
Work closely with your primary care doctor or endocrinologist. Attend all scheduled medical appointments and take medications as prescribed. A team approach that includes your retina specialist, your diabetes care team, and you as an active participant offers the best chance of preserving your vision.
Because DME can develop without symptoms, regular eye exams are essential. People with diabetes should have a comprehensive dilated eye exam at least once a year. If you have been diagnosed with diabetic retinopathy or DME, your retina specialist may recommend more frequent visits.
Do not skip these appointments, even if your vision seems fine. Early detection of new or worsening swelling allows treatment to begin before significant damage occurs.
Living with DME may require some adjustments to daily life. Good lighting can make reading and close work easier. Magnifying devices and large-print materials may help when central vision is reduced. If driving becomes difficult, discuss this honestly with your retina specialist.
Low vision rehabilitation services can help people with significant vision loss learn new strategies for maintaining independence. Your retina specialist can provide referrals to these services if needed.
When to See a Retina Specialist
If you have diabetes, whether type 1 or type 2, you should be screened for diabetic eye disease regularly. Adults with type 2 diabetes should get a dilated eye exam at the time of diagnosis and every year after. Adults with type 1 diabetes should begin annual exams within five years of diagnosis (AAO).
Certain symptoms require prompt evaluation. See a retina specialist or go to the emergency room immediately if you experience any of the following:
- Sudden increase in floaters (spots or strands drifting in your vision)
- Flashes of light in one or both eyes
- A shadow or curtain appearing over part of your vision
- Sudden vision loss in one eye
These symptoms could indicate a retinal detachment or other serious complication that requires emergency care. Do not wait for a scheduled appointment.
If you notice new blurriness, difficulty reading, or changes in how you see colors, schedule an appointment with your retina specialist soon. Even gradual changes deserve attention, because they may signal increasing swelling in the macula. Early intervention typically leads to better outcomes than waiting.
Questions and Answers
There is no certain way to prevent DME, but good diabetes management significantly reduces the risk. Maintaining target blood sugar levels, controlling blood pressure, managing cholesterol, and attending regular dilated eye exams give you the best chance of catching problems early or avoiding them altogether. Research consistently shows that patients with lower HbA1c levels develop DME at much lower rates.
The duration of treatment varies for each person. Some patients need injections for several years to keep the macula dry and stable. Others may eventually reach a point where injections can be given less frequently or paused under careful monitoring. Your retina specialist will use OCT imaging at each visit to guide decisions about treatment frequency. Stopping injections too early can allow swelling to return, so it is important to follow your treatment plan closely.
Treatment can improve vision for many patients and prevent further loss for most. However, outcomes depend on factors such as how long the swelling has been present and how well the macula responds to medication. Some patients regain significant clarity, while others stabilize at their current level. Vision that has been lost due to prolonged, untreated swelling may not fully return. Starting treatment early offers the best opportunity for improvement.
Anti-VEGF injections have a strong safety record and have been used in millions of procedures worldwide. The most common side effects are mild and temporary. These include redness at the injection site, a gritty sensation, and small floaters. Serious complications such as infection inside the eye are rare, occurring in fewer than 1 in 2,000 injections (ASRS). Your retina specialist takes careful steps to minimize risks, including cleaning the eye surface before each injection.
A diagnosis of DME does not mean blindness is inevitable. With current treatments, most patients can maintain useful vision and many experience improvement. The key factors are early detection, consistent treatment, and good diabetes management. If left untreated, DME can cause severe vision loss, including legal blindness in some cases. Keeping up with your injection schedule and regular eye exams gives you the strongest protection against significant vision loss.